CXCR2 and leukemia: To discover the functional impact of this axis on AML progression, the authors inhibited CXCR2 by pharmacologic (adopting SB332235, a selective CXCR2-inhibitor) and genetic means and observed reduced proliferation and cell cycle arrest in the leukemia bulk.